Veracyte Inc (VCYT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Veracyte Inc (VCYT) has a cash flow conversion efficiency ratio of 0.033x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($45.83 Million) by net assets ($1.39 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VCYT stock market capitalisation for the company's overall valuation and market capitalisation.
Veracyte Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Veracyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Veracyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Veracyte Inc ranked by their cash flow conversion efficiency. Explore Veracyte Inc (VCYT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nuode Investment Co Ltd
SHG:600110
|
0.013x |
|
Schneider Electric Infrastructure Limited
NSE:SCHNEIDER
|
0.108x |
|
Arcus Biosciences Inc
NYSE:RCUS
|
-0.263x |
|
LXP Industrial Trust
NYSE:LXP
|
0.019x |
|
Concentra Group Holdings Parent, Inc.
NYSE:CON
|
0.046x |
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
0.031x |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
-0.188x |
|
SF Diamond
SHE:300179
|
-0.023x |
Annual Cash Flow Conversion Efficiency for Veracyte Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Veracyte Inc from 2011 to 2025. View Veracyte Inc (VCYT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.31 Billion | $136.31 Million | 0.104x | +62.99% |
| 2024-12-31 | $1.18 Billion | $75.10 Million | 0.064x | +50.77% |
| 2023-12-31 | $1.04 Billion | $44.22 Million | 0.042x | +504.37% |
| 2022-12-31 | $1.08 Billion | $7.54 Million | 0.007x | +124.30% |
| 2021-12-31 | $1.10 Billion | $-31.62 Million | -0.029x | -25.09% |
| 2020-12-31 | $421.23 Million | $-9.71 Million | -0.023x | -70.80% |
| 2019-12-31 | $239.46 Million | $-3.23 Million | -0.013x | +92.04% |
| 2018-12-31 | $79.75 Million | $-13.52 Million | -0.170x | +73.61% |
| 2017-12-31 | $37.23 Million | $-23.91 Million | -0.642x | -36.79% |
| 2016-12-31 | $59.58 Million | $-27.98 Million | -0.470x | +10.73% |
| 2015-12-31 | $51.25 Million | $-26.96 Million | -0.526x | +21.22% |
| 2014-12-31 | $41.37 Million | $-27.63 Million | -0.668x | -96.75% |
| 2013-12-31 | $56.44 Million | $-19.16 Million | -0.339x | +76.79% |
| 2012-12-31 | $4.90 Million | $-7.17 Million | -1.462x | +7.76% |
| 2011-12-31 | $8.53 Million | $-13.52 Million | -1.585x | -- |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more